Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure

Altuntas, Y; Ozen, B; Ozturk, B; Sengul, A; Ucak, S; Ersoy, Özdal; Karul, S

doi:10.1046/j.1463-1326.2003.00283.x

Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure

Atıf İçin Kopyala

Altuntas Y., Ozen B., Ozturk B., Sengul A., Ucak S., Ersoy Ö., ...Daha Fazla

DIABETES OBESITY & METABOLISM, cilt.5, sa.6, ss.371-378, 2003 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 5 Sayı: 6
Basım Tarihi: 2003
Doi Numarası: 10.1046/j.1463-1326.2003.00283.x
Dergi Adı: DIABETES OBESITY & METABOLISM
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.371-378
Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Aim: It has been found that non-fasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. The main aim of treatment of type 2 diabetic patients is to control plasma glucose and HbA(1c) levels. In this study, we aimed to assess the effects of three different insulin regimens (group I: lispro insulin + NPH insulin, group II: lispro insulin + metformin and group III: regular insulin + NPH insulin) on overall glycaemic control and metabolic parameters in type 2 diabetic patients with secondary oral anti-diabetic drug failure.